COMBINATION METFORMIN AND ORAL CONTRACEPTIVE FOR PCOS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的核心假设是，胰岛素增敏与口服避孕药（OCP）的组合是不希望生育的PCOS女性的最佳维持治疗，因为它结合了两种药物的有益作用，并通过胰岛素增敏剂的作用，降低胰岛素抵抗和心血管疾病的风险因素。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The central hypothesis underlying this study is that a combination of insulin-sensitization to an oral contraceptive pill (OCP) is the optimal maintenance therapy for women with PCOS not desiring fertility because it combines the beneficial effects of both agents, and through the actions of the insulin-sensitizer, reduces insulin resistance and risk factors for cardiovascular disease.